Previous 10 | Next 10 |
home / stock / ipsey / ipsey news
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced its sales for the first quarter of 2018. Q1 2018 Financial highlights: Group sales growth of 23.1%, driven by Specialty Care sales growth of 27.4%, refl...
Analyses of Pooled Data of Dysport ® for the Treatment of Pediatric Lower Limb Spasticity Indicate a Consistent Safety Profile Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext:IPN)(ADR:IPSEY) (Ipsen), will present Dysport ® (abobotulinumtoxinA) dat...
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec...
Exelixis (NASDAQ: EXEL ) announces that the European Medicines Agency (EMA) has accepted for review collaboration partner Ipsen's ( OTCPK:IPSEY )( OTCPK:IPSEF ) marketing application seeking approval for CABOMETYX (cabozantinib) for previously treated patients with advanced hepatocellular ...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the European Medicines Agency (EMA), the European regulatory authority, has validated the filing of a new application for an additional indication for Cabometyx ® , for patients with previously treated advanced ...
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that its 2017 Registration Document has been filed with the French “Autorité des Marchés Financiers” (AMF) on 23 March 2018 and registered under the number D.18-0180. The document is avail...
Exelixis (NASDAQ: EXEL ) announces that commercialization partner Ipsen ( OTCPK:IPSEY )( OTCPK:IPSEF ) has received a positive opinion from the European Commission's Committee for Medicinal Products for Human Use (CHMP) backing approval for CABOMETYX (cabozantinib) for the first-line treat...
Cabozantinib is the first and only monotherapy to demonstrate superior clinical efficacy over sunitinib in treatment-naïve patients with intermediate- or poor-risk aRCC. Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Pr...
Ipsen Announces Health Canada Approval of DYSPORT THERAPEUTIC™ (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults Canada NewsWire MISSISSAUGA, ON, March 15, 2018 With this approval, DYSPORT THERAPEUTIC now has the broadest label of all approved...
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...